From the Research
Risankizumab can potentially cause hypertriglyceridemia, though it is not among the most commonly reported side effects. Hypertriglyceridemia (elevated triglyceride levels in the blood) has been observed in some patients taking risankizumab, which is a monoclonal antibody that targets the IL-23 cytokine and is primarily used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. If you are taking risankizumab (brand names include Skyrizi), it's essential to have regular blood work done to monitor your lipid profile, especially if you have pre-existing lipid abnormalities or risk factors for cardiovascular disease. The mechanism behind this potential side effect likely relates to risankizumab's immunomodulatory effects, as cytokine signaling pathways can influence lipid metabolism. Some studies suggest that omega-3 fatty acids may be beneficial in managing hypertriglyceridemia, as they have been shown to reduce triglyceride levels and improve cardiovascular outcomes 1. However, the primary concern with risankizumab-induced hypertriglyceridemia is the potential increased risk of cardiovascular disease, and patients should be closely monitored and managed accordingly. Key considerations for managing hypertriglyceridemia in patients taking risankizumab include:
- Regular monitoring of lipid profiles
- Dietary modifications to reduce triglyceride levels
- Consideration of additional medications, such as omega-3 fatty acids or statins, to manage triglyceride levels
- Reassessment of the risks and benefits of continuing risankizumab therapy in patients who develop significant hypertriglyceridemia. It is crucial to weigh the benefits of risankizumab therapy against the potential risks, including hypertriglyceridemia, and to closely monitor patients for any adverse effects 2.